| Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer A Leonetti, S Sharma, R Minari, P Perego, E Giovannetti, M Tiseo British journal of cancer 121 (9), 725-737, 2019 | 1095 | 2019 |
| Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer A Leonetti, B Wever, G Mazzaschi, YG Assaraf, C Rolfo, F Quaini, M Tiseo, ... Drug Resistance Updates 46, 100644, 2019 | 187 | 2019 |
| BRAF in non-small cell lung cancer (NSCLC): pickaxing another brick in the wall A Leonetti, F Facchinetti, G Rossi, R Minari, A Conti, L Friboulet, M Tiseo, ... Cancer treatment reviews 66, 82-94, 2018 | 183 | 2018 |
| Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab … A Cortellini, M Di Maio, O Nigro, A Leonetti, DL Cortinovis, JGJV Aerts, ... Journal for immunotherapy of cancer 9 (4), 2021 | 116 | 2021 |
| Soluble PD-L1 and circulating CD8+ PD-1+ and NK cells enclose a prognostic and predictive immune effector score in immunotherapy treated NSCLC patients G Mazzaschi, R Minari, A Zecca, A Cavazzoni, V Ferri, C Mori, A Squadrilli, ... Lung Cancer 148, 1-11, 2020 | 93 | 2020 |
| Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges A Leonetti, F Facchinetti, R Minari, A Cortellini, CD Rolfo, E Giovannetti, ... Cellular oncology 42, 261-273, 2019 | 88 | 2019 |
| Small cell lung cancer: novel treatments beyond immunotherapy JJ Meijer, A Leonetti, G Airò, M Tiseo, C Rolfo, E Giovannetti, M Vahabi Seminars in cancer biology 86, 376-385, 2022 | 76 | 2022 |
| MicroRNAs as a drug resistance mechanism to targeted therapies in EGFR-mutated NSCLC: Current implications and future directions A Leonetti, YG Assaraf, PD Veltsista, B El Hassouni, M Tiseo, ... Drug Resistance Updates 42, 1-11, 2019 | 74 | 2019 |
| Immune-related adverse events of pembrolizumab in a large real-world cohort of patients with NSCLC with a PD-L1 expression≥ 50% and their relationship with clinical outcomes A Cortellini, A Friedlaender, GL Banna, G Porzio, M Bersanelli, ... Clinical lung cancer 21 (6), 498-508. e2, 2020 | 72 | 2020 |
| Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy S Buti, A Leonetti, A Dallatomasina, M Bersanelli Core evidence, 23-36, 2016 | 67 | 2016 |
| Phase II, open-label, single-arm, multicenter study to assess the activity and safety of alectinib as neoadjuvant treatment in surgically resectable stage III ALK-positive … A Leonetti, R Minari, L Boni, L Gnetti, M Verzè, L Ventura, L Musini, ... Clinical Lung Cancer 22 (5), 473-477, 2021 | 49 | 2021 |
| Smoking status during first‐line immunotherapy and chemotherapy in NSCLC patients: A case–control matched analysis from a large multicenter study A Cortellini, A De Giglio, K Cannita, DL Cortinovis, R Cornelissen, ... Thoracic Cancer 12 (6), 880-889, 2021 | 47 | 2021 |
| Concurrent acquired BRAF V600E mutation and MET amplification as resistance mechanism of first-line osimertinib treatment in a patient with EGFR-mutated NSCLC R Minari, P Bordi, S La Monica, A Squadrilli, A Leonetti, L Bottarelli, ... Journal of Thoracic Oncology 13 (6), e89-e91, 2018 | 45 | 2018 |
| The role of the microbiome in cancer and therapy efficacy: focus on lung cancer A Halley, A Leonetti, A Gregori, M Tiseo, DM Deng, E Giovannetti, ... Anticancer research 40 (9), 4807-4818, 2020 | 39 | 2020 |
| COVID-19 in lung cancer patients receiving ALK/ROS1 inhibitors A Leonetti, F Facchinetti, T Zielli, E Brianti, M Tiseo European Journal of Cancer 132, 122-124, 2020 | 39 | 2020 |
| Small cell lung cancer transformation as a resistance mechanism to osimertinib in epidermal growth factor receptor-mutated lung adenocarcinoma: case report and literature review A Leonetti, R Minari, G Mazzaschi, L Gnetti, S La Monica, R Alfieri, ... Frontiers in Oncology 11, 642190, 2021 | 37 | 2021 |
| Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma A Leonetti, F Leonardi, M Bersanelli, S Buti Therapeutics and clinical risk management, 799-806, 2017 | 30 | 2017 |
| Hype or hope–Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC? F Papini, J Sundaresan, A Leonetti, M Tiseo, C Rolfo, GJ Peters, ... Critical Reviews in Oncology/Hematology 166, 103454, 2021 | 25 | 2021 |
| Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes A Cortellini, A Leonetti, A Catino, P Pizzutillo, B Ricciuti, A De Giglio, ... Clinical and Translational Oncology 22, 844-851, 2020 | 25 | 2020 |
| Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study S Buti, M Bersanelli, A Viansone, A Leonetti, C Masini, R Ratta, ... Cancer Treatment and Research Communications 22, 100161, 2020 | 24 | 2020 |
